Condition
Sickle B+ Thalassemia
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (4)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04691323Not ApplicableActive Not Recruiting
The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
NCT04688411Not ApplicableRecruiting
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
NCT04675645Not ApplicableCompleted
Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App
NCT04678037Not ApplicableCompleted
Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study
Showing all 4 trials